Loading
Leads breast medical oncology at Samsung Medical Center and has driven Korean participation in the HER2 and CDK4/6 trials that changed practice.
Yeon Hee Park is Professor of Medical Oncology at Samsung Medical Center in Seoul, where she leads the breast cancer programme. She has driven Korean participation in the HER2 and CDK4/6 trials that changed practice, contributing to the trastuzumab deruxtecan, palbociclib and ribociclib programmes and to Korean genomic cohorts of young-onset breast cancer. Her publications include the Young-PEARL trial of palbociclib plus exemestane with a GnRH agonist against capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer. Her interests are HER2-positive disease, young-onset breast cancer and endocrine therapy.
| Title | Journal | Year |
|---|---|---|
| Palbociclib plus exemestane with GnRH agonist versus capecitabine in premenopausal HR+ metastatic breast cancer (Young-PEARL) | Lancet Oncology | 2019 |
| DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer | New England Journal of Medicine | 2022 |
| DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group | New England Journal of Medicine | 2022 |
| KEYNOTE-522: adding pembrolizumab before and after surgery in early triple-negative breast cancer | New England Journal of Medicine | 2022 |
For HER2-positive metastatic breast cancer that has progressed after trastuzumab and a taxane, trastuzumab deruxtecan is now the standard second-line treatment and T-DM1 has moved later in the sequence. The benefit is large enough that ADC design, not just the target, is understood to be what matters. Patients need lung monitoring because of the risk of pneumonitis.
Patients whose breast cancer was previously called HER2-negative may now be eligible for an effective HER2-directed drug if their tumour has even low-level HER2 staining, so pathology reports must now distinguish HER2-low (1+ or 2+/ISH-negative) from HER2-zero. This applies to metastatic disease after at least one line of chemotherapy; it does not mean these patients benefit from trastuzumab or other older HER2 drugs.
For stage II-III triple-negative breast cancer, chemotherapy plus pembrolizumab before surgery and pembrolizumab alone afterwards is now the standard approach worldwide, and the survival gain is real, not just a surrogate. It does not apply to stage I disease or to hormone-receptor-positive or HER2-positive cancers. The price is a year of immunotherapy with a meaningful chance of a permanent endocrine side effect such as hypothyroidism or adrenal insufficiency.
Shares DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group, Trastuzumab deruxtecan, HER2, HER2-positive breast cancer.
Shares DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer, DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group, CDK4/6, Palbociclib.
Shares DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer, DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group, Trastuzumab deruxtecan, HER2.
Shares DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer, Trastuzumab deruxtecan, HER2, HER2-positive breast cancer.
Shares KEYNOTE-522: adding pembrolizumab before and after surgery in early triple-negative breast cancer, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
Shares DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group, Trastuzumab deruxtecan, HER2, HER2-positive breast cancer.
Shares DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer, Trastuzumab deruxtecan, HER2, HER2-positive breast cancer.
Shares CDK4/6, Palbociclib, HR-positive / HER2-negative breast cancer.